ACADIA PHARMACEUTICALS INC (ACAD)       16.73  +0.45 (+2.76%)

16.73  +0.45 (+2.76%)

US0042251084 - Common Stock - After market: 16.73 0 (0%)

ACADIA PHARMACEUTICALS INC16.73

NASDAQ:ACAD (9/27/2022, 4:16:44 PM)+0.45 (+2.76%)

After market: 16.73 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-08 2022-08-08/amc Earnings (Next) 11-07 2022-11-07
Ins Owners 0.16% Inst Owners 94.53%
Market Cap 2.71B Shares 161.84M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 70.77
IPO 05-27 2004-05-27

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACAD Daily chart

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 540 full-time employees. The company went IPO on 2004-05-27. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The firm has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The firm also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Company Info

ACADIA PHARMACEUTICALS INC

3611 Valley Centre Dr Ste 300

San Diego CALIFORNIA 92130

P: 18585582871.0

CEO: Stephen R. Davis

Employees: 540

Website: https://acadia.com/

ACAD Twits

Here you can normally see the latest stock twits on ACAD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example